Sphingolipids in Cancer - 1st Edition - ISBN: 9780128142233

Sphingolipids in Cancer, Volume 140

1st Edition

Serial Volume Editors: Charles Chalfant Paul Fisher
Serial Editors: Kenneth Tew
Hardcover ISBN: 9780128142233
Imprint: Academic Press
Published Date: 1st August 2018
Page Count: 312
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

1. Mechanisms of ceramide-dependent cancer cell death

  Besim Ogretmen

2. Sphingolipids as regulators of autophagy and endocytic trafficking

  Hong-Gang Wang and Megan Young

3. Role and function of sphingomyelin biosynthesis in the development of cancer

  Chiara Luberto

4. Neutral Sphingomyelinases in Cancer: Friend or Foe?

  Christopher J. Clarke

5. Sphingolipid rendezvous at the crossroad of NAFLD and senescence

  Mariana Nikolova-Karakashian

6. Ceramide signaling and p53 pathways

  Natalia Krupenko

7. The role of ceramide-1-phosphate in tumor cell survival and dissemination

  Antonio Gomez-Muñoz

8. The onus of sphingolipid enzymes in cancer drug resistance

  Myles C. Cabot

9. Targeting Sphingosine Kinases for the Treatment of Cancer

  Charles D. Smith

10. Interdiction of sphingolipid metabolism in cancer - revisited

  Christina Voelkel-Johnson

11. Ceramide and exosomes: a novel target in cancer biology and therapy

  Erhard Bieberich

12. Ceramide and exosomes: a novel target in cancer biology and therapy

  Mark Kester

13. Side effects in cancer therapy: are sphingolipids to blame?

  Stefka Spassieva


Sphingolipids in Cancer, Volume 140, the latest release in the Advances in Cancer Research series, provides invaluable information on the exciting and fast-moving field of cancer research. Topics discussed in this updated volume include Mechanisms of ceramide-dependent cancer cell death, Sphingolipids as regulators of autophagy and endocytic trafficking, The role and function of sphingomyelin biosynthesis in the development of cancer, Neutral sphingomyelinases in cancer: Friend or foe?, Sphingolipid rendezvous at the crossroad of NAFLD and senescence, Ceramide signaling and p53 pathways, Sphingolipid regulation of RNA Biology in cancer phenotypes, The role of ceramide-1-phosphate in tumor cell survival and dissemination, and more.

Key Features

  • Provides information on cancer research, with this release focusing on sphingolipids
  • Offers outstanding and original reviews on a range of cancer research topics
  • Serves as an indispensable reference for researchers and students alike


Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.


No. of pages:
© Academic Press 2018
Academic Press
Hardcover ISBN:

Ratings and Reviews

About the Serial Volume Editors

Charles Chalfant Serial Volume Editor

Professor Charles Chalfant heads up the Chalfant Laboratory and is the director of the Lipidomic Facility at Virgina Commonwealth University. The Chalfant laboratory is currently focused on two major areas of cell signaling and human pathophysiologies: 1) lipid and oncogenic regulation of alternative splicing; and 2) the regulation of eicosanoid synthesis in inflammation and cancer.

Affiliations and Expertise

Director of Lipidomics Facility, Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, USA

Paul Fisher Serial Volume Editor

Paul B. Fisher, M.Ph., Ph.D., is an accomplished molecular biologist investigating the mechanisms involved in cancer development and progression in order to define improved methods for cancer prevention, detection and therapy. Fisher pioneered a powerful technique to study gene expression in specific tissues or cell types known as subtraction hybridization, which he has used to identify genes involved in many important and medically relevant physiological processes including cancer, neurodegeneration and infectious diseases. Studies in his laboratory focus on understanding the molecular and biochemical reasons for cancer development with a specific focus on understanding how cancers spread, a process called metastasis. The ultimate aim is to use this collected knowledge to bring new, more effective prevention techniques, diagnostic approaches and therapies from the laboratory bench to the patient’s bedside. This is epitomized by his studies involving mda-7/IL-24, a gene that was discovered in his laboratory and has displayed significant clinical efficacy in a phase 1 clinical trial when injected directly into advanced cancers using a form of viral gene therapy. Using a novel cancer terminator virus, Ad.5/3-CTV, that is designed to replicate only within cancer cells while delivering the immune-modulating and toxic mda-7/IL-24 gene, Fisher and his clinical colleagues are developing a clinical trial in patients with glioblastoma multiforme, the most common and deadly form of brain cancer. Fisher has been consistently funded by the National Institutes of Health (NIH) over the past 35 years and is among the top 5 percent of NIH funded investigators during this period. He has published over 500 primary papers and reviews, served on numerous NIH study sections and government and private grant review panels and has over 55 issued patents. He is the recipient of multiple National Cancer Institute (NCI) Program Project Grants; investigator initiated R01 grants from the NIH, NCI and National Institute of General Medical Sciences (NIGMS); private foundation grants from the National Foundation for Cancer Research and the Samuel Waxman Cancer Research Foundation; and an Institutional Research and Academic Career Development Award from the NIH focusing on preparing students from groups underrepresented in the sciences for research careers. Fisher is Professor and Chair of the Department of Human and Molecular Genetics at the Virginia Commonwealth University (VCU) School of Medicine, Founding Director of the VCU Institute of Molecular Medicine and Thelma Newmeyer Corman Chair in Cancer Research and co-leader of the Cancer Molecular Genetics research program at VCU Massey Cancer Center.

Affiliations and Expertise

VCU Institute of Molecular Medicine, VA, USA

About the Serial Editors

Kenneth Tew Serial Editor

Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USA

The Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

Affiliations and Expertise

Department of Cell and Molecular Pharmacology, Medical University of South Carolina, USA